Activated Prothrombin Complex Concentrates for the Treatment of Factor Xa Inhibitor-Associated Spontaneous Intracerebral Hemorrhage. [PDF]
J Pharm Technol, 2023 Rowe AS +5 more
europepmc +1 more source
Comparing Direct Factor Xa Inhibitors and Warfarin in the Prevention of Stroke in Patients with Atrial Fibrillation [PDF]
, 2016 Objective: To evaluate the overall efficacy, advantages, and disadvantages of treatment with direct factor Xa inhibitors as compared to warfarin in the prevention of stroke in patients with atrial fibrillation.
Lof, Alessandra, Pillai, Stephanie
core
Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells. [PDF]
BMC Cardiovasc Disord, 2023 Sohma R +8 more
europepmc +1 more source
거머리로부터 혈액응고에 관련된 kallikrein 및 factor Xa 억제제의 특성분석
, 1998 학위논문(박사) - 한국과학기술원 : 생물과학과, 1998.8, [ viii, 87 p. ]I. Plasma kallikrein inhibitor: A new serine proteinase inhibitor of plasma kallikrein was screened and purified from a native Korean leech species, Hirudo nipponia.
Kim, Dong-Ryoung, 김동령
core
Laboratory monitoring of direct factor Xa inhibitor novel oral anticoagulants (DOAC) is not mandatory however, it is useful in certain clinical situations including acute care, especially before interventional procedures.
Noguchi, Fuka
core
Clinical trials update: recent and ongoing studies in anticoagulation for atrial fibrillation
Open Access Journal of Clinical Trials, 2013 James W WislerDivision of Cardiology, Duke University Hospital, Durham, NC, USAAbstract: Atrial fibrillation is the most common sustained cardiac arrhythmia in the adult population, with a marked increased risk associated with age.
Wisler JW
doaj
Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study. [PDF]
West J Emerg Med, 2023 Singer AJ +7 more
europepmc +1 more source
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. [PDF]
Res Pract Thromb Haemost, 2023 Dobesh PP +11 more
europepmc +1 more source
Thromboembolic risk and factor Xa inhibitor use in nephrotic syndrome: a pilot study in a predominantly Hispanic cohort. [PDF]
Clin Kidney JFernando PC +5 more
europepmc +1 more source
Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor-associated major bleeding: A real-world analysis of Medicare beneficiaries. [PDF]
J Am Coll Emerg Physicians Open, 2023 Williams JM +6 more
europepmc +1 more source